Acacia Pharma Group plc, of Cambridge, U.K., reported results from a pivotal phase III study testing Baremsis (amisulpride injection, formerly APD421) for the treatment of established postoperative nausea and vomiting (PONV), which the firm said further support efficacy previously shown in PONV alone, and in combination with standard antiemetics in phase III prophylaxis studies. The study compared two doses of Baremsis, a dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery, who had not previously received any prophylactic antiemetics. )